Success Story

Peroxitech raises $25M Series A

Peroxitech Inc., announced the successful completion of a $25M Series A financing round that will help to advance its lead candidate, PIP-2, for the treatment of acute lung injury (ALI) into clinical development.  The company was launched in 2016 through the UPstart program at PCI and was co-founded by Aron Fisher, MD, Director, Institute for Environmental Medicine and Sheldon Feinstein, PhD, Senior Research Director, Institute for Environmental Medicine. Peroxitech is also evaluating PIP-2 for several other high unmet need areas where modulation of oxidative injury signaling pathways may allow better treatment options for patients suffering from various types of inflammatory syndromes.

Skip to content